Abstract
HCV NS3, a serine protease, that when bound to NS-4A cofactor facilitates development of mature virons by catalyzing cleavage of a single polyprotein to form functional and structural proteins of HCV. X-ray structure of the enzyme reveal a very shallow binding pocket at the catalytic site which makes development of inhibitors a daunting task. Various novel approaches have been used to design, preorganized, depeptidized macrocyclic inhibitors linking the P2-P4 residues and P1-P3 groups. The design and structure activity relationship of these macrocyclic inhibitors are reviewed in the following article. X-ray structure of inhibitor bound to the active site of the enzyme is also discussed. Macrocyclization proved to be an effective tool for depeptidization of peptidic inhibitors, imparting enhanced metabolic stability and improved pharmacokinetic properties in the resultant molecules.
Keywords: Macrocyclization, HCV, NS3 protease, BILN-2061, depeptidization
Current Topics in Medicinal Chemistry
Title: Macrocyclic Inhibitors of HCV NS3-4A Protease: Design and Structure Activity Relationship
Volume: 7 Issue: 13
Author(s): Srikanth Venkatraman and F. George Njoroge
Affiliation:
Keywords: Macrocyclization, HCV, NS3 protease, BILN-2061, depeptidization
Abstract: HCV NS3, a serine protease, that when bound to NS-4A cofactor facilitates development of mature virons by catalyzing cleavage of a single polyprotein to form functional and structural proteins of HCV. X-ray structure of the enzyme reveal a very shallow binding pocket at the catalytic site which makes development of inhibitors a daunting task. Various novel approaches have been used to design, preorganized, depeptidized macrocyclic inhibitors linking the P2-P4 residues and P1-P3 groups. The design and structure activity relationship of these macrocyclic inhibitors are reviewed in the following article. X-ray structure of inhibitor bound to the active site of the enzyme is also discussed. Macrocyclization proved to be an effective tool for depeptidization of peptidic inhibitors, imparting enhanced metabolic stability and improved pharmacokinetic properties in the resultant molecules.
Export Options
About this article
Cite this article as:
Srikanth Venkatraman and F. George Njoroge , Macrocyclic Inhibitors of HCV NS3-4A Protease: Design and Structure Activity Relationship, Current Topics in Medicinal Chemistry 2007; 7 (13) . https://dx.doi.org/10.2174/156802607781212202
DOI https://dx.doi.org/10.2174/156802607781212202 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment and Prevention of Alcohol Hangover
Current Drug Abuse Reviews Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluations of Cytotoxic and Antiangiogenic Triterpenoids-Jacaranone Conjugates
Medicinal Chemistry TTR Fibril Formation Inhibitors: Is there a SAR?
Current Medicinal Chemistry Quinoline-based Compounds as Key Candidates to Tackle Drug Discovery Programs of Microbicidal Agents
Current Pharmaceutical Design Advanced Mass Spectrometry-Based Methods for the Analysis of Conformational Integrity of Biopharmaceutical Products
Current Pharmaceutical Biotechnology Gene Therapy of Chronic Pain
Current Gene Therapy Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases
Current Medicinal Chemistry Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Anti-Cancer Agents in Medicinal Chemistry Should we Target Allergen Protease Activity to Decrease the Burden of Allergic Airway Inflammation?
Inflammation & Allergy - Drug Targets (Discontinued) Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design Characterization of Mutants of Sulfolobus solfataricus Signature Amidase Able to Hydrolyse R-Ketoprofen Amide
Protein & Peptide Letters Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis
Current Pharmaceutical Design Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation
Current Drug Delivery Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Harnessing CD36 to Rein in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets PPARs and Diabetes-Associated Atherosclerosis
Current Pharmaceutical Design Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry